par Lytrivi, Maria 
;Igoillo Esteve, Mariana ;Cnop, Miriam
Référence Current opinion in pharmacology, 43, page (40-45)
Publication Publié, 2018-08
;Igoillo Esteve, Mariana ;Cnop, Miriam Référence Current opinion in pharmacology, 43, page (40-45)
Publication Publié, 2018-08
Article révisé par les pairs
| Résumé : | Type 2 diabetes is a common complex disease. Relatively little is known about the underlying pathophysiology. Mild islet inflammation has been suggested to play a pathogenic role; here we review the available evidence. Mild islet inflammation is histologically detected in pancreas sections of type 2 diabetic patients. In experimental models, it can be triggered by excess nutrients, amyloid, lipopolysaccharide, and endoplasmic reticulum and oxidative stress. Transcriptome studies do not consistently identify pro-inflammatory gene expression signatures in type 2 diabetic islets, and genetic evidence calls into question the causality of inflammation. Several anti-inflammatory medications confer a modest glucose-lowering effect, supporting the role for inflammation in type 2 diabetes. Whether these anti-inflammatory therapies target inflammation in islets or in other metabolically relevant tissues remains unknown. |
